JAMA Oncology

Journal

Publication Venue For

  • Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.  6:1355-1362. 2020
  • Seeing (Hearing Loss) with Fresh Eyes.  6:1335-1337. 2020
  • Association of Sedentary Behavior with Cancer Mortality in Middle-aged and Older US Adults.  6:1210-1217. 2020
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.  6:676-684. 2020
  • Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients with Osteosarcoma.  6:724-734. 2020
  • Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors before and after Transition of Imatinib to Generic Status.  6:542-546. 2020
  • Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis 2020
  • Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 29 cancer groups, 1990 to 2017: A systematic analysis for the global burden of disease study.  5:1749-1768. 2019
  • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma.  5:1141-1149. 2019
  • Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.  5:1066. 2019
  • Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women with Early-Stage Breast Cancer: A Randomized Clinical Trial.  5:710-714. 2019
  • Safety and Efficacy of Durvalumab with or Without Tremelimumab in Patients with PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.  5:195-203. 2019
  • Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.  4. 2018
  • Possible underestimation of the provision of palliative care.  4:884-885. 2018
  • A magnetic resonance imaging–based prediction model for prostate biopsy risk stratification.  4:678-685. 2018
  • Association of mismatch repair mutation with age at cancer onset in lynch syndrome implications for stratified surveillance strategies.  3:E1-E5. 2017
  • Hospital-based end-of-life care and costs for older patients with malignant brain tumors.  3:1581-1582. 2017
  • Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease.  3:1253-1256. 2017
  • Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525.  3:784-792. 2017
  • Resource use and medicare costs during lay navigation for geriatric patients with cancer.  3:817-825. 2017
  • Drawing the Line in Risk-Reducing Gynecologic Surgery in Women with a BRCA Mutation.  2:1409-1411. 2016
  • Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study.  2:1277-1286. 2016
  • The Global Burden of Cancer 2013.  1:505-527. 2015
  • Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A children's oncology group study.  1:287-295. 2015
  • International Standard Serial Number (issn)

  • 2374-2437
  • Electronic International Standard Serial Number (eissn)

  • 2374-2445